ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis)

Genetics in Medicine

Volumn 16, Issue 1, 2014, Pages 101-116

  Hegde, Madhuri ^a   Ferber, Mathew ^b   Mao, Rong ^b   Samowitz, Wade ^b   Ganguly, Arupa ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

colorectal cancer; familial adenomatous polyposis; Lynch syndrome; MYH associated polyposis

Indexed keywords

ADENOMATOUS POLYPOSIS COLI; ALGORITHMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; FEMALE; GENETIC TESTING; GUIDELINE ADHERENCE; HUMANS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84893653548     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2013.166     Document Type: Article

References (107)

1. Goodenberger M, Lindor NM. Lynch syndrome and MYH-associated polyposis: review and testing strategy. J Clin Gastroenterol 2011;45:488-500.
2. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-2460.
3. Peterlongo P, Mitra N, Sanchez de Abajo A, et al. Increased frequency of disease-causing MYH mutations in colon cancer families. Carcinogenesis 2006;27:2243-2249.
4. Coates R, Williams M, Melillo S, Gudgeon J. Genetic testing for lynch syndrome in individuals newly diagnosed with colorectal cancer to reduce morbidity and mortality from colorectal cancer in their relatives. PLoS Curr 2011;3:RRN1246.
5. Stoffel EM. Lynch Syndrome/Hereditary Non-polyposis Colorectal Cancer (HNPCC). Minerva Gastroenterol Dietol p.2010;56:45-53.
6. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35-41.
7. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009;11:42-65.
8. Steinhagen E, Shia J, Markowitz AJ, et al. Systematic immunohistochemistry screening for Lynch syndrome in early age-of-onset colorectal cancer patients undergoing surgical resection. J Am Coll Surg 2012;214:61-67.
9. Walsh J, Arora M, Hosenfeld C, Ladabaum U, Kuppermann M, Knight SJ. Preferences for genetic testing to identify hereditary colorectal cancer: perspectives of high-risk patients, community members, and clinicians. J Cancer Educ 2012;27:112-119.
10. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2011;155:69-79.
11. Jackson GL, Zullig LL, Zafar SY, et al. Using NCCN clinical practice guidelines in oncology to measure the quality of colorectal cancer care in the veterans health administration. J Natl Compr Canc Netw 2013;11:431-441.
12. Benson AB 3rd, Bekaii-Saab T, Chan E, et al. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2013;11:141-52; quiz 152.
13. Poonacha TK, Go RS. Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines. J Clin Oncol 2011;29:186-191.
14. Bellcross CA, Bedrosian SR, Daniels E, et al. Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Genet Med 2012;14:152-162.
15. Singh MM, Singh E, Miller H, Strum WB, Coyle W. Colorectal cancer screening in women with endometrial cancer: are we following the guidelines? J Gastrointest Cancer 2012;43:190-195.
16. Kotake K. [Comparison between JSCCR and NCCN guidelines for the treatment of colorectal cancer]. Nippon Rinsho 2011;69(suppl 3):242-246.
17. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257.
18. Raedle J, Trojan J, Brieger A, et al. Bethesda guidelines: relation to microsatellite instability and MLH1 promoter methylation in patients with colorectal cancer. Ann Intern Med 2001;135(8 Pt 1):566-576.
19. Wüllenweber HP, Sutter C, Autschbach F, et al. Evaluation of Bethesda guidelines in relation to microsatellite instability. Dis Colon Rectum 2001;44:1281-1289.
20. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-425.
21. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on HNPCC. Anticancer Res 1994;14(4B):1661-1664.
22. Vasen HF. Review article: The Lynch syndrome (hereditary nonpolyposis colorectal cancer). Aliment Pharmacol Ther 2007;26(suppl 2):113-126.
23. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-268.
24. Umar A, Risinger JI, Hawk ET, Barrett JC. Testing guidelines for hereditary nonpolyposis colorectal cancer. Nat Rev Cancer 2004;4:153-158.
25. Win AK, Jenkins MA, Buchanan DD, et al. Determining the frequency of de novo germline mutations in DNA mismatch repair genes. J Med Genet 2011;48:530-534.
26. Felton KE, Gilchrist DM, Andrew SE. Constitutive deficiency in DNA mismatch repair: is it time for Lynch III? Clin Genet 2007;71:499-500.
27. Felton KE, Gilchrist DM, Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin Genet 2007;71:483-498.
28. De Vos M, Hayward BE, Picton S, Sheridan E, Bonthron DT. Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am J Hum Genet 2004;74:954-964.
29. Lynch PM. The hMSH2 and hMLH1 genes in hereditary nonpolyposis colorectal cancer. Surg Oncol Clin N Am 2009;18:611-624.
30. Genuardi M, Anti M, Capozzi E, et al. MLH1 and MSH2 constitutional mutations in colorectal cancer families not meeting the standard criteria for hereditary nonpolyposis colorectal cancer. Int J Cancer 1998;75:835-839.
31. Giráldez MD, Balaguer F, Bujanda L, et al. MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer. Clin Cancer Res 2010;16:5402-5413.
32. Duraturo F, Liccardo R, Cavallo A, De Rosa M, Grosso M, Izzo P. Association of low-risk MSH3 and MSH2 variant alleles with Lynch syndrome: probability of synergistic effects. Int J Cancer 2011;129:1643-1650.
33. Nicolaides NC, Papadopoulos N, Liu B, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994;371:75-80.
34. Talseth-Palmer BA, McPhillips M, Groombridge C, Spigelman A, Scott RJ. MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer. Hered Cancer Clin Pract 2010;8:5.
35. Yuan ZQ, Wong N, Foulkes WD, et al. A missense mutation in both hMSH2 and APC in an Ashkenazi Jewish HNPCC kindred: implications for clinical screening. J Med Genet 1999;36:790-793.
36. Pérez-Carbonell L, Ruiz-Ponte C, Guarinos C, et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut 2012;61:865-872.
37. Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology 2010;56:167-179.
38. Bartley AN, Luthra R, Saraiya DS, Urbauer DL, Broaddus RR. Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing. Cancer Prev Res (Phila) 2012;5:320-327.
39. Plaschke J, Krüger S, Dietmaier W, et al.; German HNPCC Consortium. Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue. Hum Mutat 2004;23:285.
40. Plaschke J, Linnebacher M, Kloor M, et al. Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor. Eur J Hum Genet 2006;14:561-566.
41. Kim YH, Kakar S, Cun L, Deng G, Kim YS. Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps. Int J Cancer 2008;123:2587-2593.
42. Kim YS, Deng G. Epigenetic changes (aberrant DNA methylation) in colorectal neoplasia. Gut Liver 2007;1:1-11.
43. Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004;10(1 Pt 1):191-195.
44. Deng DJ, Zhou J, Zhu BD, Ji JF, Harper JC, Powell SM. Silencing-specific methylation and single nucleotide polymorphism of hMLH1 promoter in gastric carcinomas. World J Gastroenterol 2003;9:26-29.
45. Deng G, Peng E, Gum J, Terdiman J, Sleisenger M, Kim YS. Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer. Br J Cancer 2002;86:574-579.
46. Deng D, Deng G, Smith MF, et al. Simultaneous detection of CpG methylation and single nucleotide polymorphism by denaturing high performance liquid chromatography. Nucleic Acids Res 2002;30:E13.
47. Deng D, Deng G, Lü Y. [Analysis of the methylation in CpG island by denaturing high-performance liquid chromatography]. Zhonghua Yi Xue Za Zhi 2001;81:158-161.
48. Deng G, Chen A, Pong E, Kim YS. Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression. Oncogene 2001;20:7120-7127.
49. Deng G, Chen A, Hong J, Chae HS, Kim YS. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 1999;59:2029-2033.
50. Rahner N, Friedrichs N, Steinke V, et al. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome. J Pathol 2008;214:10-16.
51. Valle L, Carbonell P, Fernandez V, et al. MLH1 germline epimutations in selected patients with early-onset non-polyposis colorectal cancer. Clin Genet 2007;71:232-237.
52. Niessen RC, Hofstra RM, Westers H, et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer 2009;48:737-744.
53. Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet 2012;49:151-157.
54. Loughrey MB, Waring PM, Tan A, et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 2007;6:301-310.
55. Bonadona V, Bonaïti B, Olschwang S, et al.; French Cancer Genetics Network. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;305:2304-2310.
56. Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 2009;137:1621-1627.
57. Stoffel EM, Chittenden A. Genetic testing for hereditary colorectal cancer: challenges in identifying, counseling, and managing high-risk patients. Gastroenterology 2010;139:1436-41, 1441.e1.
58. Shi SR, Datar R, Liu C, et al. DNA extraction from archival formalin-fixed, paraffin-embedded tissues: heat-induced retrieval in alkaline solution. Histochem Cell Biol 2004;122:211-218.
59. Hitchins MP, Ward RL. Erasure of MLH1 methylation in spermatozoaimplications for epigenetic inheritance. Nat Genet 2007;39:1289.
60. Hitchins MP, Ward RL. MLH1 germ-line epimutations: is there strong evidence of its inheritance? Gastroenterology 2008;134:359-360.
61. Hitchins MP, Ward RL. Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J Med Genet 2009;46:793-802.
62. Koh DC, Luchtefeld MA, Kim DG, Attal H, Monroe T, Ingersoll K. Microsatellite instability and MLH1 hypermethylation-incidence and significance in colorectal polyps in young patients. Colorectal Dis 2007;9:521-526.
63. Ogino S, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8:209-217.
64. Fukushima T, Katayama Y, Watanabe T, et al. Promoter hypermethylation of mismatch repair gene hMLH1 predicts the clinical response of malignant astrocytomas to nitrosourea. Clin Cancer Res 2005;11:1539-1544.
65. Frazier ML, Sinicrope FA, Amos CI, et al. Loci for efficient detection of microsatellite instability in hereditary non-polyposis colorectal cancer. Oncol Rep 1999;6:497-505.
66. Ebinger M, Sotlar K, Weber A, Bock CT, Bültmann BD, Kandolf R. Simplified detection of microsatellite instability in colorectal cancer without the need for corresponding germline DNA analysis. J Clin Pathol 2006;59:1114-1115.
67. Buhard O, Suraweera N, Lectard A, Duval A, Hamelin R. Quasimonomorphic mononucleotide repeats for high-level microsatellite instability analysis. Dis Markers 2004;20:251-257.
68. Suraweera N, Duval A, Reperant M, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002;123:1804-1811.
69. Pyatt R, Chadwick RB, Johnson CK, Adebamowo C, de la Chapelle A, Prior TW. Polymorphic variation at the BAT-25 and BAT-26 loci in individuals of African origin. Implications for microsatellite instability testing. Am J Pathol 1999;155:349-353.
70. Søreide K. Molecular testing for microsatellite instability and DNA mismatch repair defects in hereditary and sporadic colorectal cancers-ready for prime time? Tumour Biol 2007;28:290-300.
71. Hegde M, Blazo M, Chong B, Prior T, Richards C. Assay validation for identification of hereditary nonpolyposis colon cancer-causing mutations in mismatch repair genes MLH1, MSH2, and MSH6. J Mol Diagn 2005;7:525-534.
72. Hendriks YM, Jagmohan-Changur S, van der Klift HM, et al. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome). Gastroenterology 2006;130:312-322.
73. Richards CS, Bale S, Bellissimo DB, et al.; Molecular Subcommittee of the ACMG Laboratory Quality Assurance Committee. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med 2008;10:294-300.
74. Maddalena A, Bale S, Das S, Grody W, Richards S; ACMG Laboratory Quality Assurance Committee. Technical standards and guidelines: molecular genetic testing for ultra-rare disorders. Genet Med 2005;7:571-583.
75. Tayeh MK, Chin EL, Miller VR, Bean LJ, Coffee B, Hegde M. Targeted comparative genomic hybridization array for the detection of single-and multiexon gene deletions and duplications. Genet Med 2009;11:232-240.
76. Rumilla K, Schowalter KV, Lindor NM, et al. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J Mol Diagn 2011;13:93-99.
77. Lynch HT, Lynch JF, Snyder CL, Riegert-Johnson D. EPCAM deletions, Lynch syndrome, and cancer risk. Lancet Oncol 2011;12:5-6.
78. Knudson A. Alfred Knudson and his two-hit hypothesis. (Interview by Ezzie Hutchinson). Lancet Oncol 2001;2:642-645.
79. White RL. Colon cancer. Molecular biology of the APC protein. Pathol Biol 1997;45:240-244.
80. Umar A, Viner JL, Hawk ET. The future of colon cancer prevention. Ann N Y Acad Sci 2001;952:88-108.
81. Claes K, Dahan K, Tejpar S, et al. The genetics of familial adenomatous polyposis (FAP) and MutYH-associated polyposis (MAP). Acta Gastroenterol Belg 2011;74:421-426.
82. Hes FJ, Nielsen M, Bik EC, et al. Somatic APC mosaicism: an underestimated cause of polyposis coli. Gut 2008;57:71-76.
83. Rennert G, Almog R, Tomsho LP, et al. Colorectal polyps in carriers of the APC I1307K polymorphism. Dis Colon Rectum 2005;48:2317-2321.
84. Shtoyerman-Chen R, Friedman E, Figer A, et al. The I1307K APC polymorphism: prevalence in non-Ashkenazi Jews and evidence for a founder effect. Genet Test 2001;5:141-146.
85. Popat S, Stone J, Coleman G, et al. Prevalence of the APC E1317Q variant in colorectal cancer patients. Cancer Lett 2000;149:203-206.
86. Grover S, Kastrinos F, Steyerberg EW, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA 2012;308:485-492.
87. Castellsagué E, González S, Nadal M, et al. Detection of APC gene deletions using quantitative multiplex PCR of short fluorescent fragments. Clin Chem 2008;54:1132-1140.
88. De la Fuente MK, Alvarez KP, Letelier AJ. et al. Mutational screening of the APC gene in Chilean families with familial adenomatous polyposis: nine novel truncating mutations. Dis Colon Rectum 2007;50:2142-2148.
89. Gavert N, Yaron Y, Naiman T, et al. Molecular analysis of the APC gene in 71 Israeli families: 17 novel mutations. Hum Mutat 2002;19:664.
90. De Filippo C, Luceri C, Caderni G, et al. Mutations of the APC gene in human sporadic colorectal cancers. Scand J Gastroenterol 2002;37:1048-1053.
91. Diehl F, Traverso G. High-throughput in vitro translation. Discov Med 2003;3:44-45.
92. Gite S, Lim M, Carlson R, Olejnik J, Zehnbauer B, Rothschild K. A highthroughput nonisotopic protein truncation test. Nat Biotechnol 2003;21:194-197.
93. Leite JS, Isidro G, Martins M, et al. Is prophylactic colectomy indicated in patients with MYH-associated polyposis? Colorectal Dis 2005;7:327-331.
94. Isidro G, Laranjeira F, Pires A, et al. Germline MUTYH (MYH) mutations in Portuguese individuals with multiple colorectal adenomas. Hum Mutat 2004;24:353-354.
95. Wang L, Baudhuin LM, Boardman LA, et al. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology 2004;127:9-16.
96. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003;348:791-799.
97. Venesio T, Molatore S, Cattaneo F, Arrigoni A, Risio M, Ranzani GN. High frequency of MYH gene mutations in a subset of patients with familial adenomatous polyposis. Gastroenterology 2004;126:1681-1685.
98. Colebatch A, Hitchins M, Williams R, Meagher A, Hawkins NJ, Ward RL. The role of MYH and microsatellite instability in the development of sporadic colorectal cancer. Br J Cancer 2006;95:1239-1243.
99. Al-Tassan N, Eisen T, Maynard J, et al. Inherited variants in MYH are unlikely to contribute to the risk of lung carcinoma. Hum Genet 2004;114:207-210.
100. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C-T:A mutations in colorectal tumors. Nat Genet 2002;30:227-232.
101. Gismondi V, Meta M, Bonelli L, et al. Prevalence of the Y165C, G382D and 1395del GGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas. Int J Cancer 2004;109:680-684.
102. Croitoru ME, Cleary SP, Di Nicola N, et al. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst 2004;96:1631-1634.
103. Enholm S, Hienonen T, Suomalainen A, et al. Proportion and phenotype of MYH-associated colorectal neoplasia in a population-based series of Finnish colorectal cancer patients. Am J Pathol 2003;163:827-832.
104. Jones S, Emmerson P, Maynard J, et al. Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C-T:A mutations. Hum Mol Genet 2002;11:2961-2967.
105. Buchanan D, Young J. A perspective on bi-allelic MUTYH mutations in patients with hyperplastic polyposis syndrome. Gastroenterology 2009;136:2407-2408.
106. Scheuner MT, Edelen MO, Hilborne LH, Lubin IM; RAND Molecular Genetic Test Report Advisory Board. Effective communication of molecular genetic test results to primary care providers. Genet Med 2013;15:444-449.
107. Scheuner MT, Hilborne L, Brown J, Lubin IM; members of the RAND Molecular Genetic Test Report Advisory Board. A report template for molecular genetic tests designed to improve communication between the clinician and laboratory. Genet Test Mol Biomarkers 2012;16: 761-769.